|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
To further define the role of PTEN/MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods.
|
9788441 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
This report describes a novel mouse model that overexpresses ERG and lacks PTEN with the majority of mice developing prostate tumors by 6 mo.
|
25007053 |
2014 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We have quantitatively analyzed the mRNA levels of TMPRSS2-ERG, ERG, PTEN, and AR (n = 83), as well as ERG immunostaining (n = 78) in a series of prostate tumors.
|
25939480 |
2015 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, ADT combined with vaccination, specifically a DNA vaccine encoding the ligand-binding domain of the AR, led to improved antitumor responses as measured by tumor volumes and delays in the emergence of castrate-resistant prostate tumors in two murine prostate cancer models (Myc-CaP and prostate-specific PTEN-deficient mice).
|
29051161 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The PTEN gene, located on 10q23, has recently been implicated as a candidate tumor suppressor gene in brain, breast and prostate tumors.
|
9331072 |
1997 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here, we show that AKT2 is exclusively required for PTEN-deficient prostate tumor spheroid maintenance, whereas AKT1 is dispensable. shRNA silencing of AKT2 but not AKT1 promotes regression of prostate cancer xenografts.
|
24838891 |
2014 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, we showed in preclinical models that BRG1 antagonist selectively inhibited the progression of PTEN-deficient prostate tumors.
|
30496141 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in one tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.
|
9671408 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Retroviral expression of constitutively active Notch-1 in human prostate tumor cell lines resulted in increased PTEN gene expression.
|
19479935 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
|
17826033 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence.
|
16637073 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30% of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53.
|
25381262 |
2015 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN loss stimulates prostate tumor progression by sustaining AKT activation.Nowak et al.(2019.<i>J.
|
31145683 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Immunofluorescence data and western blot analyses determined that a lentivirus containing a 5'UTR derived from FGF-2 is the best candidate for directing selective gene expression in the prostate tumors of PTEN(-/-) mice in vivo.
|
21921943 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis.
|
21930937 |
2011 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
IGF-IR expression positively correlates with PTEN and inversely correlates with NRP2 in prostate tumors.
|
22777769 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Here, we provide evidence that PTEN loss in prostate tumours upregulates the expression of ADAM17, thereby activating NOTCH signalling.
|
27941799 |
2016 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors.
|
16496415 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Alterations in the PIK3CA and PTEN genes were assessed in 40 prostate tumors (radical prostatectomy samples).
|
19443396 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We studied the sensitivity and specificity of PTEN immunohistochemistry relative to four-color fluorescence in situ hybridization (FISH) for detection of PTEN gene deletion in a multi-institutional cohort of 731 primary prostate tumors.
|
27174589 |
2016 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth.
|
25156255 |
2014 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy.
|
24993522 |
2015 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Based on the identification of mutations in sporadic breast, brain and prostate tumours, we decided to examine the potential role of PTEN in sporadic malignant melanoma.
|
9764804 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level.
|
17611019 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Finally, higher levels of Akt activation are observed in human prostate cancer cell lines and xenografts lacking PTEN/MMAC1 expression when compared with PTEN/MMAC1-positive prostate tumors or normal prostate tissue.
|
9861013 |
1998 |